Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Phase II, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing CPL409116 to Placebo, in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to MTX

NCT05374785 is registered in ClinicalTrials.gov with Celon Pharma SA as lead sponsor.

NCT NCT05374785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05374785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Phase II, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing CPL409116 to Placebo, in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to MTX
Lead sponsor
Celon Pharma SA
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2022
Completion date
May 27, 2024
Enrollment
106 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis